Growth Suppression and Mitotic Defect Induced by JNJ-7706621, an Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|12|6|625-639

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.6, 2012-07, pp. : 625-639

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclin-dependent kinases and stroke

By Park David S   Wang Fuhu   O’Hare Michael J  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 5, 2001-10 ,pp. : 557-567

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors targeting vascular endothelial growth factor receptor kinases and cyclin-dependent kinases

By  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 3, 2005-03 ,pp. : 337-341

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics

By  

Current Medicinal Chemistry, Vol. 7, Iss. 12, 2000-12 ,pp. : 1213-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

By Johnson Neil   Shapiro Geoffrey I  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 11, 2010-11 ,pp. : 1199-1212

Informa Healthcare

Access to resources Recommend Favorite

Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases

By Jackson Robert C   Barnett Anna L   McClue Steven J   Green Simon R  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 1, 2008-01 ,pp. : 131-143

Informa Healthcare

Access to resources Recommend Favorite